CalciMedica, Inc. (NASDAQ: CALC), a clinical-stage biopharmaceutical company developing CRAC channel inhibition therapies for serious inflammatory, immunologic, and cardiopulmonary diseases, announced on July 29, 2026…
Corbus Pharmaceuticals received FDA clearance to start its TEMPO‑1 registrational trial. Registrational studies are designed to provide the pivotal data needed to support a future…
July 28, 2026
Atea’s Hepatitis C Breakthrough: New Short‑Course Pill Regimen Clears Phase 3 C‑BEYOND Trial
Phase 3 C‑BEYOND in hepatitis C met both primary and secondary goals. Atea’s pill combo bemnifosbuvir/ruzasvir showed very high cure rates and a solid safety…
FiscalNote Holdings, Inc. (OTC: NOTE) is ticking higher today, with the stock up about 16% to 0.10 from a prior level around 0.0859. Shares have…
Fractyl Health Inc. (NASDAQ: GUTS) is highlighting new REMAIN‑1 data that suggest its Revita procedure may help people maintain much of their weight loss for…
The Advanced Research Projects Agency for Health (ARPA-H) is committing up to $160 million to scientists building platforms for highly personalized genetic treatments, with a…
July 09, 2026
60 Degrees Pharmaceuticals Secures New Castanospermine Opportunity in Tick-Borne Disease
60 Degrees Pharmaceuticals Inc. (NASDAQ: SXTP) has signed an exclusive option agreement with the Florida State University Research Foundation (FSURF) to advance Castanospermine for several…
July 08, 2026
Vanda Pharmaceuticals Wins FDA Rare Pediatric Disease Status For Ultra-Rare Nerve Disorder Drug
Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) has received Rare Pediatric Disease Designation from the U.S. Food and Drug Administration for VCA‑894A, an investigational antisense therapy aimed…
Clearmind Medicine Inc. (Nasdaq: CMND) is taking a meaningful step toward turning its lead compound MEAI into a nasal spray treatment for alcohol use disorder…
Biogen (NASDAQ: BIIB) is using AAIC 2026 to showcase the depth of its Alzheimer’s portfolio, including new Phase 2 data for its tau‑targeting antisense drug…
Aethlon Medical, Inc. (NASDAQ: AEMD) has announced new peer‑reviewed research supporting a mechanistic link between a novel long COVID biomarker and its Hemopurifier device, suggesting…
eXoZymes Inc (NASDAQ: EXOZ) picked up another non‑dilutive win and the stock responded, nudging higher after the company secured a new $2 million NIH grant…